| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fetal Development | 29 | 2023 | 70 | 4.940 |
Why?
|
| Pregnancy | 165 | 2023 | 2334 | 4.760 |
Why?
|
| Phthalic Acids | 8 | 2022 | 28 | 3.250 |
Why?
|
| Pregnancy, Multiple | 23 | 2019 | 32 | 3.120 |
Why?
|
| Premature Birth | 21 | 2022 | 150 | 2.870 |
Why?
|
| Maternal Exposure | 7 | 2022 | 75 | 2.560 |
Why?
|
| Pregnancy Complications | 21 | 2021 | 286 | 2.280 |
Why?
|
| Obstetric Labor, Premature | 30 | 2009 | 76 | 2.250 |
Why?
|
| Gestational Age | 48 | 2021 | 389 | 2.240 |
Why?
|
| Ultrasonography, Prenatal | 27 | 2022 | 79 | 2.120 |
Why?
|
| Birth Weight | 30 | 2021 | 186 | 2.070 |
Why?
|
| Prenatal Care | 13 | 2021 | 117 | 1.910 |
Why?
|
| Uterine Contraction | 22 | 2012 | 30 | 1.890 |
Why?
|
| Fetal Growth Retardation | 10 | 2021 | 56 | 1.650 |
Why?
|
| Infant, Newborn | 56 | 2023 | 2455 | 1.630 |
Why?
|
| Environmental Pollutants | 4 | 2021 | 180 | 1.560 |
Why?
|
| Fetal Weight | 15 | 2022 | 33 | 1.480 |
Why?
|
| Female | 170 | 2023 | 38074 | 1.480 |
Why?
|
| Twins | 21 | 2018 | 42 | 1.470 |
Why?
|
| Pregnancy, Twin | 7 | 2019 | 9 | 1.390 |
Why?
|
| Weight Gain | 11 | 2023 | 135 | 1.360 |
Why?
|
| Prospective Studies | 53 | 2023 | 3705 | 1.350 |
Why?
|
| Pregnancy Outcome | 20 | 2017 | 157 | 1.250 |
Why?
|
| Twins, Dizygotic | 8 | 2021 | 25 | 1.090 |
Why?
|
| Humans | 173 | 2023 | 68618 | 1.090 |
Why?
|
| Adult | 101 | 2022 | 21403 | 1.050 |
Why?
|
| Pregnant Women | 4 | 2022 | 50 | 1.020 |
Why?
|
| Body Composition | 5 | 2023 | 119 | 1.010 |
Why?
|
| National Institute of Child Health and Human Development (U.S.) | 12 | 2023 | 20 | 0.990 |
Why?
|
| Endocrine Disruptors | 3 | 2021 | 31 | 0.930 |
Why?
|
| Infant, Small for Gestational Age | 7 | 2021 | 46 | 0.890 |
Why?
|
| Delivery, Obstetric | 9 | 2014 | 58 | 0.880 |
Why?
|
| Tocolytic Agents | 5 | 2007 | 12 | 0.850 |
Why?
|
| Placenta | 3 | 2022 | 101 | 0.840 |
Why?
|
| Peripartum Period | 2 | 2022 | 15 | 0.830 |
Why?
|
| Asthma | 10 | 2020 | 345 | 0.810 |
Why?
|
| Growth Charts | 4 | 2021 | 16 | 0.800 |
Why?
|
| Cohort Studies | 31 | 2022 | 2358 | 0.740 |
Why?
|
| Body Mass Index | 14 | 2023 | 867 | 0.730 |
Why?
|
| Diabetes, Gestational | 6 | 2021 | 81 | 0.730 |
Why?
|
| Chorion | 5 | 2019 | 13 | 0.720 |
Why?
|
| Stillbirth | 3 | 2016 | 12 | 0.700 |
Why?
|
| Pre-Eclampsia | 12 | 2019 | 202 | 0.670 |
Why?
|
| Fetus | 7 | 2022 | 157 | 0.660 |
Why?
|
| Penis | 1 | 2019 | 25 | 0.650 |
Why?
|
| Abnormalities, Drug-Induced | 2 | 2017 | 34 | 0.640 |
Why?
|
| Glucocorticoids | 4 | 2018 | 222 | 0.630 |
Why?
|
| Young Adult | 25 | 2021 | 5717 | 0.620 |
Why?
|
| Hydroxyprogesterones | 2 | 2008 | 6 | 0.620 |
Why?
|
| Diseases in Twins | 7 | 2019 | 31 | 0.610 |
Why?
|
| Mothers | 6 | 2022 | 172 | 0.590 |
Why?
|
| Infant, Premature, Diseases | 2 | 2014 | 85 | 0.580 |
Why?
|
| Fetal Monitoring | 5 | 2008 | 20 | 0.570 |
Why?
|
| Twins, Monozygotic | 4 | 2016 | 27 | 0.570 |
Why?
|
| Mental Disorders | 2 | 2022 | 659 | 0.560 |
Why?
|
| Betamethasone | 3 | 2001 | 24 | 0.560 |
Why?
|
| Prenatal Exposure Delayed Effects | 4 | 2022 | 154 | 0.540 |
Why?
|
| Monitoring, Ambulatory | 3 | 2009 | 84 | 0.540 |
Why?
|
| Triplets | 7 | 2004 | 9 | 0.520 |
Why?
|
| Pediatric Obesity | 3 | 2022 | 92 | 0.520 |
Why?
|
| South Carolina | 14 | 2021 | 2752 | 0.510 |
Why?
|
| Adipose Tissue | 2 | 2019 | 221 | 0.500 |
Why?
|
| Breast Feeding | 5 | 2021 | 159 | 0.500 |
Why?
|
| Environmental Exposure | 4 | 2021 | 269 | 0.480 |
Why?
|
| Fetal Death | 2 | 2014 | 49 | 0.470 |
Why?
|
| Fetal Membranes, Premature Rupture | 7 | 2008 | 45 | 0.460 |
Why?
|
| Infant, Newborn, Diseases | 3 | 2018 | 91 | 0.450 |
Why?
|
| Anthropometry | 6 | 2020 | 64 | 0.450 |
Why?
|
| Obesity | 9 | 2023 | 1076 | 0.450 |
Why?
|
| Fetal Blood | 2 | 2018 | 131 | 0.440 |
Why?
|
| Uterus | 7 | 2018 | 77 | 0.440 |
Why?
|
| Uterine Monitoring | 4 | 2006 | 4 | 0.430 |
Why?
|
| United States | 25 | 2023 | 7367 | 0.430 |
Why?
|
| Cervix Uteri | 7 | 2004 | 64 | 0.420 |
Why?
|
| Maternal-Fetal Exchange | 3 | 2022 | 57 | 0.420 |
Why?
|
| Beclomethasone | 2 | 2009 | 4 | 0.410 |
Why?
|
| Theophylline | 2 | 2009 | 22 | 0.410 |
Why?
|
| Progestins | 2 | 2009 | 19 | 0.400 |
Why?
|
| Overweight | 3 | 2023 | 186 | 0.390 |
Why?
|
| Adolescent | 23 | 2020 | 8912 | 0.390 |
Why?
|
| Predictive Value of Tests | 14 | 2021 | 1465 | 0.390 |
Why?
|
| Risk Factors | 25 | 2022 | 5731 | 0.370 |
Why?
|
| Reference Values | 11 | 2021 | 579 | 0.370 |
Why?
|
| Reproductive Techniques, Assisted | 2 | 2015 | 6 | 0.370 |
Why?
|
| Male | 25 | 2022 | 37321 | 0.360 |
Why?
|
| Glycerophospholipids | 1 | 2009 | 20 | 0.350 |
Why?
|
| Biometry | 2 | 2018 | 72 | 0.340 |
Why?
|
| Hemodynamics | 4 | 1999 | 705 | 0.340 |
Why?
|
| Pregnancy Complications, Infectious | 4 | 2011 | 92 | 0.330 |
Why?
|
| Pregnancy Trimester, Third | 8 | 2019 | 39 | 0.330 |
Why?
|
| Vaginal Birth after Cesarean | 2 | 2006 | 8 | 0.330 |
Why?
|
| Labor, Induced | 2 | 2006 | 18 | 0.320 |
Why?
|
| Monitoring, Physiologic | 9 | 1990 | 219 | 0.320 |
Why?
|
| Pregnancy Trimester, Second | 10 | 2018 | 58 | 0.320 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2009 | 127 | 0.320 |
Why?
|
| Phenols | 2 | 2022 | 73 | 0.300 |
Why?
|
| Infant, Low Birth Weight | 3 | 2010 | 84 | 0.290 |
Why?
|
| Tandem Mass Spectrometry | 3 | 2020 | 139 | 0.290 |
Why?
|
| Retrospective Studies | 15 | 2021 | 7277 | 0.280 |
Why?
|
| Pregnancy, High-Risk | 5 | 2015 | 14 | 0.280 |
Why?
|
| Medicaid | 1 | 2008 | 302 | 0.270 |
Why?
|
| Biomarkers | 6 | 2022 | 1593 | 0.260 |
Why?
|
| Parity | 10 | 2010 | 71 | 0.260 |
Why?
|
| Infant Mortality | 4 | 2001 | 59 | 0.260 |
Why?
|
| Maternal Nutritional Physiological Phenomena | 2 | 2020 | 37 | 0.260 |
Why?
|
| Pregnancy Trimester, First | 4 | 2022 | 43 | 0.260 |
Why?
|
| Maternal Age | 9 | 2018 | 70 | 0.250 |
Why?
|
| Alcohol Drinking | 2 | 2009 | 805 | 0.250 |
Why?
|
| Amniotic Fluid | 3 | 2019 | 30 | 0.250 |
Why?
|
| Health Promotion | 1 | 2008 | 407 | 0.240 |
Why?
|
| Socioeconomic Factors | 4 | 2020 | 955 | 0.240 |
Why?
|
| Dibutyl Phthalate | 2 | 2021 | 5 | 0.240 |
Why?
|
| Smoking | 4 | 2010 | 1452 | 0.240 |
Why?
|
| Vibration | 2 | 1995 | 32 | 0.230 |
Why?
|
| Child | 10 | 2022 | 6405 | 0.230 |
Why?
|
| Interleukin-6 | 2 | 2018 | 330 | 0.230 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2022 | 41 | 0.230 |
Why?
|
| Residence Characteristics | 2 | 2020 | 252 | 0.220 |
Why?
|
| Nifedipine | 3 | 1999 | 40 | 0.220 |
Why?
|
| Acoustic Stimulation | 2 | 1995 | 206 | 0.220 |
Why?
|
| Labor, Obstetric | 3 | 2011 | 23 | 0.220 |
Why?
|
| Progesterone | 2 | 2021 | 115 | 0.220 |
Why?
|
| Infant, Premature | 5 | 2014 | 284 | 0.210 |
Why?
|
| Longitudinal Studies | 7 | 2021 | 1054 | 0.210 |
Why?
|
| Referral and Consultation | 3 | 2018 | 383 | 0.210 |
Why?
|
| Caffeine | 1 | 2022 | 81 | 0.210 |
Why?
|
| Vascular Resistance | 4 | 1999 | 179 | 0.200 |
Why?
|
| Fibronectins | 2 | 2002 | 130 | 0.200 |
Why?
|
| Terbutaline | 3 | 1993 | 23 | 0.200 |
Why?
|
| Indomethacin | 2 | 1999 | 107 | 0.190 |
Why?
|
| Cross-Sectional Studies | 6 | 2021 | 2279 | 0.190 |
Why?
|
| Work | 1 | 2001 | 12 | 0.190 |
Why?
|
| Alkanesulfonic Acids | 1 | 2021 | 54 | 0.190 |
Why?
|
| Lactation | 2 | 2022 | 110 | 0.190 |
Why?
|
| Beverages | 1 | 2021 | 50 | 0.180 |
Why?
|
| Perinatal Death | 2 | 2019 | 4 | 0.180 |
Why?
|
| Cesarean Section | 8 | 2008 | 101 | 0.180 |
Why?
|
| Risk | 5 | 2020 | 563 | 0.180 |
Why?
|
| Stress, Psychological | 2 | 2017 | 824 | 0.180 |
Why?
|
| Prenatal Diagnosis | 2 | 2018 | 73 | 0.180 |
Why?
|
| Fluorocarbons | 1 | 2021 | 82 | 0.180 |
Why?
|
| Logistic Models | 7 | 2021 | 1420 | 0.180 |
Why?
|
| Child, Preschool | 6 | 2022 | 3187 | 0.180 |
Why?
|
| Ambulatory Care | 5 | 2008 | 340 | 0.180 |
Why?
|
| Hypertension, Pregnancy-Induced | 2 | 2019 | 28 | 0.180 |
Why?
|
| Severity of Illness Index | 7 | 2009 | 1851 | 0.180 |
Why?
|
| Fatigue | 1 | 2001 | 132 | 0.170 |
Why?
|
| Placenta Growth Factor | 1 | 2019 | 12 | 0.170 |
Why?
|
| Vitamins | 1 | 2020 | 134 | 0.170 |
Why?
|
| Inflammation | 3 | 2018 | 1030 | 0.170 |
Why?
|
| Uterine Hemorrhage | 2 | 2018 | 16 | 0.170 |
Why?
|
| Body Fluids | 1 | 1999 | 41 | 0.170 |
Why?
|
| Pulmonary Edema | 1 | 1999 | 37 | 0.170 |
Why?
|
| Fetal Movement | 3 | 1995 | 4 | 0.170 |
Why?
|
| Hydatidiform Mole | 2 | 1989 | 3 | 0.160 |
Why?
|
| Diet | 2 | 2021 | 514 | 0.160 |
Why?
|
| Eclampsia | 2 | 1989 | 16 | 0.160 |
Why?
|
| Embryonic and Fetal Development | 7 | 2003 | 74 | 0.160 |
Why?
|
| Exercise | 2 | 2022 | 658 | 0.160 |
Why?
|
| Analgesia, Obstetrical | 1 | 2018 | 15 | 0.160 |
Why?
|
| Vitamin D | 3 | 2022 | 516 | 0.160 |
Why?
|
| Uterine Neoplasms | 2 | 1989 | 99 | 0.160 |
Why?
|
| Acetylcysteine | 2 | 2012 | 296 | 0.160 |
Why?
|
| Analgesia, Epidural | 1 | 2018 | 40 | 0.160 |
Why?
|
| Depression | 2 | 2022 | 943 | 0.150 |
Why?
|
| Methylprednisolone | 1 | 2018 | 99 | 0.150 |
Why?
|
| Fever | 1 | 2018 | 96 | 0.150 |
Why?
|
| Genitalia, Male | 1 | 2017 | 14 | 0.150 |
Why?
|
| Genitalia, Female | 1 | 2017 | 20 | 0.150 |
Why?
|
| Fetal Diseases | 3 | 2011 | 64 | 0.150 |
Why?
|
| Health Status Disparities | 1 | 2020 | 326 | 0.150 |
Why?
|
| Pregnancy Trimesters | 1 | 2017 | 14 | 0.150 |
Why?
|
| Drug Therapy | 1 | 1997 | 71 | 0.140 |
Why?
|
| Antitubercular Agents | 1 | 1997 | 57 | 0.140 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1997 | 85 | 0.140 |
Why?
|
| Diphenhydramine | 1 | 1996 | 13 | 0.140 |
Why?
|
| Ritodrine | 2 | 1987 | 3 | 0.140 |
Why?
|
| Tuberculosis | 1 | 1997 | 77 | 0.140 |
Why?
|
| Contraindications | 3 | 2006 | 52 | 0.140 |
Why?
|
| Breech Presentation | 3 | 1999 | 11 | 0.130 |
Why?
|
| Odds Ratio | 6 | 2022 | 880 | 0.130 |
Why?
|
| Milk, Human | 1 | 1997 | 147 | 0.130 |
Why?
|
| Amnion | 1 | 1995 | 15 | 0.130 |
Why?
|
| Magnesium Sulfate | 1 | 1995 | 6 | 0.130 |
Why?
|
| Case-Control Studies | 4 | 2021 | 1553 | 0.130 |
Why?
|
| Employment | 2 | 2012 | 154 | 0.130 |
Why?
|
| Heart Rate | 2 | 1999 | 568 | 0.130 |
Why?
|
| Anti-Asthmatic Agents | 3 | 2004 | 56 | 0.130 |
Why?
|
| Version, Fetal | 2 | 1999 | 8 | 0.120 |
Why?
|
| Patient Education as Topic | 4 | 1998 | 425 | 0.120 |
Why?
|
| Administration, Oral | 3 | 2009 | 411 | 0.120 |
Why?
|
| Body Weight | 5 | 2018 | 554 | 0.120 |
Why?
|
| Hypertension | 3 | 1999 | 1535 | 0.120 |
Why?
|
| Depression, Postpartum | 1 | 2013 | 9 | 0.110 |
Why?
|
| Stroke Volume | 1 | 1996 | 586 | 0.110 |
Why?
|
| Time Factors | 8 | 2019 | 4655 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 772 | 0.110 |
Why?
|
| Diabetes Mellitus | 1 | 2019 | 694 | 0.110 |
Why?
|
| Heart Rate, Fetal | 2 | 1995 | 12 | 0.110 |
Why?
|
| Depressive Disorder | 1 | 2017 | 621 | 0.110 |
Why?
|
| Risk Assessment | 3 | 2017 | 2007 | 0.110 |
Why?
|
| Labor Onset | 2 | 1998 | 2 | 0.100 |
Why?
|
| Contractile Proteins | 1 | 2012 | 17 | 0.100 |
Why?
|
| Plethysmography | 1 | 2012 | 17 | 0.100 |
Why?
|
| Antihypertensive Agents | 1 | 1996 | 498 | 0.100 |
Why?
|
| Home Care Services | 3 | 2009 | 84 | 0.100 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2012 | 59 | 0.100 |
Why?
|
| Hospital-Physician Relations | 1 | 2012 | 5 | 0.100 |
Why?
|
| Body Height | 3 | 2020 | 67 | 0.100 |
Why?
|
| Blood Glucose | 3 | 2005 | 631 | 0.100 |
Why?
|
| Patient Admission | 2 | 1998 | 99 | 0.100 |
Why?
|
| Benzhydryl Compounds | 1 | 2012 | 62 | 0.100 |
Why?
|
| Lamivudine | 1 | 2011 | 24 | 0.100 |
Why?
|
| Drug Administration Schedule | 3 | 2001 | 567 | 0.100 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2011 | 28 | 0.100 |
Why?
|
| Hospital Information Systems | 1 | 2012 | 44 | 0.100 |
Why?
|
| Decision Trees | 1 | 2011 | 74 | 0.100 |
Why?
|
| Hyperemesis Gravidarum | 1 | 1991 | 4 | 0.100 |
Why?
|
| Hepatitis B | 1 | 2011 | 42 | 0.100 |
Why?
|
| Administration, Inhalation | 2 | 2009 | 187 | 0.100 |
Why?
|
| Immunoglobulins | 1 | 2011 | 97 | 0.100 |
Why?
|
| Recurrence | 3 | 2007 | 948 | 0.090 |
Why?
|
| Adiposity | 2 | 2022 | 88 | 0.090 |
Why?
|
| Cardiotocography | 1 | 1990 | 3 | 0.090 |
Why?
|
| Interleukin-1 | 1 | 2011 | 86 | 0.090 |
Why?
|
| ROC Curve | 3 | 2008 | 392 | 0.090 |
Why?
|
| Glucose | 1 | 1992 | 307 | 0.090 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 2 | 2001 | 46 | 0.090 |
Why?
|
| Tocolysis | 3 | 1998 | 3 | 0.090 |
Why?
|
| Regression Analysis | 5 | 2006 | 737 | 0.090 |
Why?
|
| Dietary Supplements | 3 | 2022 | 332 | 0.090 |
Why?
|
| Body Weights and Measures | 1 | 2010 | 11 | 0.090 |
Why?
|
| Free Radical Scavengers | 1 | 2011 | 112 | 0.090 |
Why?
|
| Lipopolysaccharides | 1 | 2012 | 455 | 0.090 |
Why?
|
| Guidelines as Topic | 2 | 2017 | 123 | 0.090 |
Why?
|
| Multivariate Analysis | 4 | 2017 | 1046 | 0.090 |
Why?
|
| Fetal Alcohol Spectrum Disorders | 1 | 2009 | 27 | 0.090 |
Why?
|
| Cardiomyopathies | 1 | 1991 | 167 | 0.090 |
Why?
|
| Labetalol | 2 | 1999 | 10 | 0.090 |
Why?
|
| Surveys and Questionnaires | 3 | 2010 | 2800 | 0.090 |
Why?
|
| Trophoblastic Neoplasms | 1 | 1989 | 4 | 0.090 |
Why?
|
| Sensitivity and Specificity | 6 | 2019 | 1753 | 0.090 |
Why?
|
| Plasticizers | 2 | 2020 | 5 | 0.080 |
Why?
|
| Labor Presentation | 2 | 1999 | 8 | 0.080 |
Why?
|
| Patient Discharge | 1 | 2012 | 294 | 0.080 |
Why?
|
| Cerebral Hemorrhage | 2 | 2001 | 198 | 0.080 |
Why?
|
| Gestonorone Caproate | 1 | 2009 | 2 | 0.080 |
Why?
|
| Communication | 1 | 2012 | 329 | 0.080 |
Why?
|
| Calcium Channel Blockers | 2 | 1999 | 138 | 0.080 |
Why?
|
| Electric Impedance | 3 | 1999 | 131 | 0.080 |
Why?
|
| Cervical Ripening | 1 | 2008 | 2 | 0.080 |
Why?
|
| Glucose Tolerance Test | 3 | 2020 | 75 | 0.080 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 1999 | 189 | 0.080 |
Why?
|
| Case Management | 1 | 2008 | 46 | 0.080 |
Why?
|
| Patient Readmission | 1 | 1991 | 267 | 0.080 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2011 | 626 | 0.080 |
Why?
|
| Dystocia | 1 | 2008 | 4 | 0.080 |
Why?
|
| Fetal Heart | 1 | 1988 | 41 | 0.080 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 649 | 0.070 |
Why?
|
| Brain Injuries | 1 | 2011 | 268 | 0.070 |
Why?
|
| Michigan | 2 | 2005 | 68 | 0.070 |
Why?
|
| Maryland | 2 | 2005 | 77 | 0.070 |
Why?
|
| Secondary Prevention | 1 | 2008 | 291 | 0.070 |
Why?
|
| Renal Dialysis | 2 | 1999 | 174 | 0.070 |
Why?
|
| Congenital Abnormalities | 2 | 1998 | 42 | 0.070 |
Why?
|
| Oxytocics | 1 | 2006 | 14 | 0.070 |
Why?
|
| Lung Diseases | 2 | 2006 | 175 | 0.070 |
Why?
|
| Cephalometry | 2 | 2017 | 19 | 0.070 |
Why?
|
| Primary Health Care | 1 | 2012 | 703 | 0.070 |
Why?
|
| Linear Models | 2 | 2021 | 521 | 0.070 |
Why?
|
| Disease Progression | 1 | 2009 | 1038 | 0.070 |
Why?
|
| Infusions, Intravenous | 3 | 1999 | 334 | 0.070 |
Why?
|
| Spirometry | 1 | 2006 | 47 | 0.070 |
Why?
|
| Follow-Up Studies | 2 | 2009 | 3259 | 0.070 |
Why?
|
| Maternal Mortality | 1 | 2005 | 16 | 0.070 |
Why?
|
| Single-Blind Method | 1 | 2006 | 249 | 0.060 |
Why?
|
| Catheterization | 1 | 2006 | 209 | 0.060 |
Why?
|
| Perception | 1 | 1986 | 189 | 0.060 |
Why?
|
| Placenta Diseases | 1 | 2005 | 5 | 0.060 |
Why?
|
| Fees and Charges | 1 | 2005 | 11 | 0.060 |
Why?
|
| Obstetrics | 1 | 2005 | 44 | 0.060 |
Why?
|
| Double-Blind Method | 5 | 2018 | 1738 | 0.060 |
Why?
|
| Physical Examination | 2 | 1998 | 152 | 0.060 |
Why?
|
| Infant | 2 | 2023 | 2891 | 0.060 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2005 | 69 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2019 | 931 | 0.060 |
Why?
|
| Pregnancy in Diabetics | 2 | 2019 | 70 | 0.060 |
Why?
|
| Tennessee | 1 | 2003 | 11 | 0.060 |
Why?
|
| District of Columbia | 1 | 2003 | 23 | 0.060 |
Why?
|
| Chicago | 1 | 2003 | 30 | 0.060 |
Why?
|
| Pennsylvania | 1 | 2003 | 46 | 0.060 |
Why?
|
| Ohio | 1 | 2003 | 64 | 0.060 |
Why?
|
| Communications Media | 1 | 2003 | 8 | 0.060 |
Why?
|
| Bronchodilator Agents | 1 | 2004 | 43 | 0.060 |
Why?
|
| California | 1 | 2003 | 99 | 0.060 |
Why?
|
| Alabama | 1 | 2003 | 98 | 0.060 |
Why?
|
| Oxytocin | 2 | 1996 | 124 | 0.060 |
Why?
|
| North Carolina | 1 | 2003 | 224 | 0.050 |
Why?
|
| Incidence | 3 | 2006 | 1603 | 0.050 |
Why?
|
| Emergencies | 3 | 1999 | 107 | 0.050 |
Why?
|
| Obstetrics and Gynecology Department, Hospital | 2 | 1993 | 11 | 0.050 |
Why?
|
| Docosahexaenoic Acids | 1 | 2022 | 12 | 0.050 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2022 | 9 | 0.050 |
Why?
|
| Hospitalization | 1 | 2008 | 978 | 0.050 |
Why?
|
| Forced Expiratory Volume | 3 | 2010 | 87 | 0.050 |
Why?
|
| Models, Biological | 2 | 2020 | 981 | 0.050 |
Why?
|
| Estriol | 1 | 2001 | 2 | 0.050 |
Why?
|
| Physicians | 1 | 2005 | 324 | 0.050 |
Why?
|
| Quality of Life | 1 | 2010 | 1515 | 0.050 |
Why?
|
| Diet Surveys | 1 | 2021 | 24 | 0.050 |
Why?
|
| Respiratory Sounds | 1 | 2020 | 35 | 0.050 |
Why?
|
| Diethylhexyl Phthalate | 1 | 2020 | 3 | 0.050 |
Why?
|
| Cyclohexanes | 1 | 2020 | 10 | 0.050 |
Why?
|
| Esters | 1 | 2020 | 22 | 0.050 |
Why?
|
| Dicarboxylic Acids | 1 | 2020 | 16 | 0.050 |
Why?
|
| Endometritis | 1 | 2000 | 29 | 0.050 |
Why?
|
| Retreatment | 1 | 2000 | 59 | 0.050 |
Why?
|
| Evidence-Based Medicine | 1 | 2003 | 438 | 0.050 |
Why?
|
| Cerebral Ventricles | 1 | 2000 | 36 | 0.050 |
Why?
|
| Saliva | 1 | 2001 | 142 | 0.050 |
Why?
|
| Chorioamnionitis | 1 | 2000 | 40 | 0.040 |
Why?
|
| Chromatography, Liquid | 1 | 2020 | 120 | 0.040 |
Why?
|
| Gastrointestinal Agents | 1 | 2020 | 51 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2020 | 39 | 0.040 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2020 | 60 | 0.040 |
Why?
|
| Intensive Care, Neonatal | 2 | 2016 | 38 | 0.040 |
Why?
|
| Educational Status | 1 | 2001 | 273 | 0.040 |
Why?
|
| Sewage | 1 | 2019 | 23 | 0.040 |
Why?
|
| Glycoproteins | 1 | 2001 | 238 | 0.040 |
Why?
|
| Sleep | 1 | 2022 | 263 | 0.040 |
Why?
|
| Term Birth | 1 | 2019 | 12 | 0.040 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 1999 | 34 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 2 | 2019 | 1026 | 0.040 |
Why?
|
| North America | 1 | 2019 | 112 | 0.040 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 1999 | 15 | 0.040 |
Why?
|
| Body Fluid Compartments | 1 | 2019 | 4 | 0.040 |
Why?
|
| Feeding Behavior | 1 | 2021 | 224 | 0.040 |
Why?
|
| Skinfold Thickness | 1 | 2019 | 11 | 0.040 |
Why?
|
| Anxiety | 1 | 2022 | 422 | 0.040 |
Why?
|
| Medical Records | 1 | 1999 | 121 | 0.040 |
Why?
|
| Obstetric Labor Complications | 2 | 1999 | 20 | 0.040 |
Why?
|
| Maternal Welfare | 1 | 1998 | 17 | 0.040 |
Why?
|
| Humerus | 1 | 2018 | 23 | 0.040 |
Why?
|
| Renal Insufficiency | 1 | 1999 | 121 | 0.040 |
Why?
|
| Organ Size | 1 | 2018 | 242 | 0.040 |
Why?
|
| Radioisotopes | 1 | 1997 | 40 | 0.040 |
Why?
|
| Hospitals, Urban | 1 | 2017 | 46 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 1997 | 55 | 0.040 |
Why?
|
| Length of Stay | 3 | 2005 | 780 | 0.040 |
Why?
|
| Sex Factors | 3 | 2005 | 1266 | 0.040 |
Why?
|
| Health Behavior | 1 | 2021 | 458 | 0.040 |
Why?
|
| Electrocardiography | 2 | 1991 | 601 | 0.040 |
Why?
|
| Blood Pressure | 3 | 1999 | 1451 | 0.040 |
Why?
|
| Femur | 1 | 2018 | 113 | 0.040 |
Why?
|
| Cardiography, Impedance | 1 | 1996 | 14 | 0.040 |
Why?
|
| Abdomen | 1 | 2017 | 80 | 0.040 |
Why?
|
| Observer Variation | 1 | 1997 | 330 | 0.030 |
Why?
|
| Quality Assurance, Health Care | 1 | 2018 | 177 | 0.030 |
Why?
|
| Ultrasonography | 3 | 1997 | 453 | 0.030 |
Why?
|
| Random Allocation | 2 | 1988 | 442 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2019 | 403 | 0.030 |
Why?
|
| Glomerulonephritis, IGA | 1 | 1996 | 12 | 0.030 |
Why?
|
| Prognosis | 3 | 1996 | 2093 | 0.030 |
Why?
|
| Gynecology | 1 | 1996 | 46 | 0.030 |
Why?
|
| Zygote | 1 | 1995 | 3 | 0.030 |
Why?
|
| Drug Overdose | 1 | 1996 | 67 | 0.030 |
Why?
|
| alpha-Fetoproteins | 1 | 1995 | 22 | 0.030 |
Why?
|
| Sound Spectrography | 1 | 1995 | 14 | 0.030 |
Why?
|
| Nutrition Assessment | 1 | 1995 | 43 | 0.030 |
Why?
|
| Sound | 1 | 1995 | 16 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2019 | 310 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 786 | 0.030 |
Why?
|
| Cardiac Output | 1 | 1995 | 133 | 0.030 |
Why?
|
| Research Design | 1 | 2019 | 729 | 0.030 |
Why?
|
| Vitamin D Deficiency | 1 | 2017 | 292 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 2 | 2011 | 504 | 0.030 |
Why?
|
| Cost Savings | 2 | 2011 | 110 | 0.030 |
Why?
|
| Age Factors | 1 | 1999 | 1864 | 0.030 |
Why?
|
| Labor Stage, Third | 1 | 1993 | 1 | 0.030 |
Why?
|
| Abortion, Spontaneous | 1 | 1993 | 17 | 0.030 |
Why?
|
| Clinical Trials as Topic | 2 | 1988 | 848 | 0.030 |
Why?
|
| Neoplasms | 1 | 2005 | 1667 | 0.030 |
Why?
|
| Prevalence | 1 | 2017 | 1619 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 2077 | 0.030 |
Why?
|
| Receptors, Oxytocin | 1 | 2012 | 9 | 0.030 |
Why?
|
| Pharmacy and Therapeutics Committee | 1 | 1992 | 7 | 0.030 |
Why?
|
| Antidepressive Agents | 1 | 2013 | 216 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 1993 | 1040 | 0.030 |
Why?
|
| Captopril | 1 | 1991 | 22 | 0.030 |
Why?
|
| Digoxin | 1 | 1991 | 24 | 0.020 |
Why?
|
| Furosemide | 1 | 1991 | 45 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 1991 | 87 | 0.020 |
Why?
|
| Connexin 43 | 1 | 2012 | 62 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 1 | 2012 | 160 | 0.020 |
Why?
|
| Drug Utilization | 1 | 1992 | 119 | 0.020 |
Why?
|
| Dilatation, Pathologic | 1 | 1991 | 58 | 0.020 |
Why?
|
| Substance-Related Disorders | 1 | 2001 | 1242 | 0.020 |
Why?
|
| Models, Animal | 1 | 2012 | 252 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2011 | 114 | 0.020 |
Why?
|
| Birth Order | 1 | 1991 | 5 | 0.020 |
Why?
|
| Psychotherapy | 1 | 2013 | 253 | 0.020 |
Why?
|
| Ovulation Induction | 1 | 1991 | 9 | 0.020 |
Why?
|
| Viral Load | 1 | 2011 | 127 | 0.020 |
Why?
|
| Ethanol | 1 | 1997 | 893 | 0.020 |
Why?
|
| Pharmacists | 1 | 1992 | 125 | 0.020 |
Why?
|
| Necrosis | 1 | 1991 | 239 | 0.020 |
Why?
|
| Aftercare | 1 | 2012 | 114 | 0.020 |
Why?
|
| Fluid Therapy | 1 | 1991 | 59 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2012 | 447 | 0.020 |
Why?
|
| Fertilization in Vitro | 1 | 1991 | 47 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2012 | 432 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 1997 | 1070 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2011 | 396 | 0.020 |
Why?
|
| Calcium, Dietary | 1 | 2009 | 35 | 0.020 |
Why?
|
| Treatment Outcome | 3 | 2004 | 7029 | 0.020 |
Why?
|
| Micronutrients | 1 | 2009 | 31 | 0.020 |
Why?
|
| Morbidity | 1 | 2010 | 130 | 0.020 |
Why?
|
| Head | 1 | 2010 | 59 | 0.020 |
Why?
|
| Mice | 2 | 2012 | 8474 | 0.020 |
Why?
|
| Patient Participation | 1 | 1990 | 146 | 0.020 |
Why?
|
| Injections, Intramuscular | 1 | 2009 | 44 | 0.020 |
Why?
|
| Infant Nutritional Physiological Phenomena | 1 | 2009 | 72 | 0.020 |
Why?
|
| Hospitals, University | 2 | 2004 | 169 | 0.020 |
Why?
|
| Echocardiography | 1 | 1991 | 515 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2010 | 201 | 0.020 |
Why?
|
| Adaptation, Physiological | 1 | 2009 | 189 | 0.020 |
Why?
|
| Shoulder | 1 | 1987 | 37 | 0.020 |
Why?
|
| Antioxidants | 1 | 2009 | 304 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 1990 | 1140 | 0.020 |
Why?
|
| Modems | 1 | 1986 | 1 | 0.020 |
Why?
|
| Cytokines | 1 | 2011 | 866 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2012 | 1293 | 0.020 |
Why?
|
| Middle Aged | 2 | 2019 | 21147 | 0.020 |
Why?
|
| Twin Studies as Topic | 1 | 2005 | 3 | 0.020 |
Why?
|
| Hormones | 1 | 2005 | 42 | 0.020 |
Why?
|
| Florida | 1 | 2005 | 221 | 0.010 |
Why?
|
| Animals | 2 | 2012 | 20881 | 0.010 |
Why?
|
| Respiratory Function Tests | 1 | 2003 | 123 | 0.010 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2004 | 186 | 0.010 |
Why?
|
| Nutritional Requirements | 1 | 2003 | 57 | 0.010 |
Why?
|
| Chi-Square Distribution | 2 | 1993 | 546 | 0.010 |
Why?
|
| Trial of Labor | 1 | 2001 | 5 | 0.010 |
Why?
|
| Uterine Rupture | 1 | 2001 | 4 | 0.010 |
Why?
|
| Lung | 1 | 2006 | 849 | 0.010 |
Why?
|
| Safety | 1 | 2001 | 145 | 0.010 |
Why?
|
| Infertility | 1 | 2000 | 26 | 0.010 |
Why?
|
| Brain | 1 | 2011 | 2176 | 0.010 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 1998 | 24 | 0.010 |
Why?
|
| Spinal Dysraphism | 1 | 1998 | 8 | 0.010 |
Why?
|
| Hernia, Umbilical | 1 | 1998 | 10 | 0.010 |
Why?
|
| Patient Care Planning | 1 | 1998 | 108 | 0.010 |
Why?
|
| False Negative Reactions | 1 | 1998 | 63 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 1998 | 95 | 0.010 |
Why?
|
| Hydrocephalus | 1 | 1998 | 40 | 0.010 |
Why?
|
| Hospital Costs | 1 | 1998 | 117 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1987 | 2324 | 0.010 |
Why?
|
| Vagina | 1 | 1997 | 88 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1995 | 219 | 0.010 |
Why?
|
| Health Care Costs | 1 | 1998 | 346 | 0.010 |
Why?
|
| Abnormalities, Multiple | 1 | 1995 | 109 | 0.010 |
Why?
|
| Oligohydramnios | 1 | 1993 | 7 | 0.010 |
Why?
|
| Ductus Arteriosus | 1 | 1993 | 13 | 0.010 |
Why?
|
| Umbilical Veins | 1 | 1993 | 54 | 0.010 |
Why?
|
| Injections | 1 | 1993 | 119 | 0.010 |
Why?
|
| Nurse Midwives | 1 | 1993 | 21 | 0.010 |
Why?
|
| Concurrent Review | 1 | 1992 | 2 | 0.010 |
Why?
|
| Hysterectomy | 1 | 1992 | 64 | 0.010 |
Why?
|
| Premedication | 1 | 1992 | 49 | 0.010 |
Why?
|
| Inservice Training | 1 | 1992 | 68 | 0.010 |
Why?
|
| Patient Care Team | 1 | 1993 | 311 | 0.010 |
Why?
|
| Drug Prescriptions | 1 | 1992 | 135 | 0.010 |
Why?
|
| Practice Patterns, Physicians' | 1 | 1992 | 504 | 0.000 |
Why?
|
| Electrophysiology | 1 | 1986 | 160 | 0.000 |
Why?
|
| Feasibility Studies | 1 | 1987 | 652 | 0.000 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 1987 | 529 | 0.000 |
Why?
|